Clinical Advances in
Evidence shows that there are disparities in multiple myeloma (MM) treatment between clinical trials and real-world outcomes. Awareness of potential practice-changing new data in frontline, maintenance, and relapsed/refractory (RR) MM, new treatment pathways, as well as emerging treatment challenges will provide guidance on how to achieve deep and longer responses based on both clinical and social needs. This collection provides important information and discussions among experts on the latest advances in MM, with the ultimate goal of improving patient outcomes.
Supported by an independent educational grant from
Steering Committee Chair
University of Newcastle
Newcastle, United Kingdom
University of Athens
Athens, Greece
University Hospital Würzburg
Würzburg, Germany
Emory University
Atlanta, Georgia, United States
University Hospital of Salamanca
Salamanca, Spain
University Hospital of Nantes
Nantes, France